Clinical, neurophysiological and serological clues for the diagnosis of neuromyotonia and distinction from cramp-fasciculation syndrome

[1]  J. Honnorat,et al.  Autoimmune neuromyotonia , 2022, Current opinion in neurology.

[2]  P. Calabresi,et al.  Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia , 2021, European journal of neurology.

[3]  D. Bennett,et al.  Leucine‐Rich Glioma‐Inactivated 1 versus Contactin‐Associated Protein‐like 2 Antibody Neuropathic Pain: Clinical and Biological Comparisons , 2021, Annals of neurology.

[4]  J. Honnorat,et al.  Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[5]  K. Claeys,et al.  Neuromuscular hyperexcitability syndromes , 2021, Current opinion in neurology.

[6]  Gianvito Masi,et al.  Assessing the role of a tissue-based assay in the diagnostic algorithm of autoimmune encephalitis , 2021, Journal of Neuroimmunology.

[7]  S. Aaron,et al.  Utility of stimulus induced after discharges in the evaluation of peripheral nerve hyperexcitability: Old wine in a new bottle? , 2020, Journal of the peripheral nervous system : JPNS.

[8]  M. Elsensohn,et al.  Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[9]  S. Irani,et al.  Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2 , 2020, Practical Neurology.

[10]  C. Vollono,et al.  Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic aetiology , 2020, European journal of neurology.

[11]  A. Boon,et al.  AANEM – IFCN glossary of terms in neuromuscular electrodiagnostic medicine and ultrasound , 2020, Clinical Neurophysiology.

[12]  E. Marchioni,et al.  Acquired neuromyotonia in thymoma‐associated myasthenia gravis: a clinical and serological study , 2019, European journal of neurology.

[13]  A. Vincent,et al.  Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia , 2018, JAMA neurology.

[14]  J. Britton,et al.  Expanded phenotypes and outcomes among 256 LGI1/CASPR2‐IgG–positive patients , 2017, Annals of neurology.

[15]  A. Cebrian-Silla,et al.  Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis , 2017, Neurology.

[16]  A. Vincent,et al.  Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies , 2017, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  P. S. Sillevis Smitt,et al.  The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies , 2016, Neurology.

[18]  Z. Simmons,et al.  Isaacs syndrome: A review , 2015, Muscle & nerve.

[19]  E. Lancaster,et al.  Paraneoplastic Disorders in Thymoma Patients , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  Masahiko Watanabe,et al.  Autoantibodies to Epilepsy-Related LGI1 in Limbic Encephalitis Neutralize LGI1-ADAM22 Interaction and Reduce Synaptic AMPA Receptors , 2013, The Journal of Neuroscience.

[21]  S. Scherer,et al.  Acquired neuromyotonia heralding recurrent thymoma in myasthenia gravis. , 2013, JAMA neurology.

[22]  Lyell K. Jones,et al.  Cramp‐fasciculation syndrome in patients with and without neural autoantibodies , 2013, Muscle & nerve.

[23]  A. Vincent,et al.  Morvan syndrome: Clinical and serological observations in 29 cases , 2012, Annals of neurology.

[24]  K. Strauss,et al.  Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia , 2011, Annals of neurology.

[25]  A. Vincent,et al.  Peripheral nerve hyperexcitability , 2011, Neurology.

[26]  A. Vincent,et al.  Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia , 2010, Brain : a journal of neurology.

[27]  M. Benatar,et al.  Accuracy of repetitive nerve stimulation for diagnosis of the cramp–fasciculation syndrome , 2007, Muscle & nerve.

[28]  K. Mills,et al.  Clinical electrophysiological characterization of the acquired neuromyotonia phenotype of autoimmune peripheral nerve hyperexcitability , 2006, Muscle & nerve.

[29]  V. Lennon,et al.  Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability , 2002, Muscle & nerve.

[30]  K. Mills,et al.  Phenotypic variants of autoimmune peripheral nerve hyperexcitability. , 2002, Brain : a journal of neurology.

[31]  G Plazzi,et al.  Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. , 2001, Brain : a journal of neurology.

[32]  L. Gutmann,et al.  When is myokymia neuromyotonia? , 2001, Muscle & nerve.

[33]  T. Heiman-Patterson,et al.  Cramp,fasciculation syndrome , 1991, Neurology.

[34]  B. Katirji.  Peripheral nerve hyperexcitability. , 2019, Handbook of clinical neurology.

[35]  Elio Lugaresi,et al.  Agrypnia excitata. , 2011, Sleep medicine.